Literature DB >> 26696331

Rheumatoid Arthritis-Associated Interstitial Lung Disease and Idiopathic Pulmonary Fibrosis: Shared Mechanistic and Phenotypic Traits Suggest Overlapping Disease Mechanisms.

Francisco Paulin1, Tracy J Doyle2, Elaine A Fletcher3, Dana P Ascherman4, Ivan O Rosas2.   

Abstract

The prevalence of clinically evident interstitial lung disease in patients with rheumatoid arthritis is approximately 10%. An additional 33% of undiagnosed patients have interstitial lung abnormalities that can be detected with high-resolution computed tomography. Rheumatoid arthritis-interstitial lung disease patients have three times the risk of death compared to those with rheumatoid arthritis occurring in the absence of interstitial lung disease, and the mortality related to interstitial lung disease is rising. Rheumatoid arthritis-interstitial lung disease is most commonly classified as the usual interstitial pneumonia pattern, overlapping mechanistically and phenotypically with idiopathic pulmonary fibrosis, but can occur in a non-usual interstitial pneumonia pattern, mainly nonspecific interstitial pneumonia. Based on this, we propose two possible pathways to explain the coexistence of rheumatoid arthritis and interstitial lung disease: (i) Rheumatoid arthritis-interstitial lung disease with a non-usual interstitial pneumonia pattern may come about when an immune response against citrullinated peptides taking place in another site (e.g. the joints) subsequently affects the lungs; (ii) Rheumatoid arthritis-interstitial lung disease with a usual interstitial pneumonia pattern may represent a disease process in which idiopathic pulmonary fibrosis-like pathology triggers an immune response against citrullinated proteins that promotes articular disease indicative of rheumatoid arthritis. More studies focused on elucidating the basic mechanisms leading to different sub-phenotypes of rheumatoid arthritis-interstitial lung disease and the overlap with idiopathic pulmonary fibrosis are necessary to improve our understanding of the disease process and to define new therapeutic targets.

Entities:  

Mesh:

Year:  2015        PMID: 26696331      PMCID: PMC4690466     

Source DB:  PubMed          Journal:  Rev Invest Clin        ISSN: 0034-8376            Impact factor:   1.451


  55 in total

Review 1.  American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

2.  Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis.

Authors:  Thomas J Richards; Naftali Kaminski; Fred Baribaud; Susan Flavin; Carrie Brodmerkel; Daniel Horowitz; Katherine Li; Jiin Choi; Louis J Vuga; Kathleen O Lindell; Melinda Klesen; Yingze Zhang; Kevin F Gibson
Journal:  Am J Respir Crit Care Med       Date:  2012-01-01       Impact factor: 21.405

3.  Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.

Authors:  Deborah Assayag; Brett M Elicker; Thomas H Urbania; Thomas V Colby; Bo Hyoung Kang; Jay H Ryu; Talmadge E King; Harold R Collard; Dong Soon Kim; Joyce S Lee
Journal:  Radiology       Date:  2013-10-28       Impact factor: 11.105

4.  Methotrexate in psoriasis: 26 years' experience with low-dose long-term treatment.

Authors:  U F Haustein; M Rytter
Journal:  J Eur Acad Dermatol Venereol       Date:  2000-09       Impact factor: 6.166

5.  Detection of Rheumatoid Arthritis-Interstitial Lung Disease Is Enhanced by Serum Biomarkers.

Authors:  Tracy J Doyle; Avignat S Patel; Hiroto Hatabu; Mizuki Nishino; Guodong Wu; Juan C Osorio; Maria F Golzarri; Andres Traslosheros; Sarah G Chu; Michelle L Frits; Christine K Iannaccone; Diane Koontz; Carl Fuhrman; Michael E Weinblatt; Souheil Y El-Chemaly; George R Washko; Gary M Hunninghake; Augustine M K Choi; Paul F Dellaripa; Chester V Oddis; Nancy A Shadick; Dana P Ascherman; Ivan O Rosas
Journal:  Am J Respir Crit Care Med       Date:  2015-06-15       Impact factor: 21.405

6.  Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease.

Authors:  E J Kim; B M Elicker; F Maldonado; W R Webb; J H Ryu; J H Van Uden; J S Lee; T E King; H R Collard
Journal:  Eur Respir J       Date:  2009-12-08       Impact factor: 16.671

7.  Shared immunological targets in the lungs and joints of patients with rheumatoid arthritis: identification and validation.

Authors:  A Jimmy Ytterberg; Vijay Joshua; Gudrun Reynisdottir; Nataliya K Tarasova; Dorothea Rutishauser; Elena Ossipova; Aase Haj Hensvold; Anders Eklund; C Magnus Sköld; Johan Grunewald; Vivianne Malmström; Per Johan Jakobsson; Johan Rönnelid; Leonid Padyukov; Roman A Zubarev; Lars Klareskog; Anca I Catrina
Journal:  Ann Rheum Dis       Date:  2014-05-09       Impact factor: 19.103

8.  Telomerase and telomere length in pulmonary fibrosis.

Authors:  Tianju Liu; Matthew Ullenbruch; Yoon Young Choi; Hongfeng Yu; Lin Ding; Antoni Xaubet; Javier Pereda; Carol A Feghali-Bostwick; Peter B Bitterman; Craig A Henke; Annie Pardo; Moises Selman; Sem H Phan
Journal:  Am J Respir Cell Mol Biol       Date:  2013-08       Impact factor: 6.914

9.  Biomarkers of rheumatoid arthritis-associated interstitial lung disease.

Authors:  Juan Chen; Tracy J Doyle; Yongliang Liu; Rohit Aggarwal; Xiaoping Wang; Yonghong Shi; Sheng Xiang Ge; Heqing Huang; Qingyan Lin; Wen Liu; Yongjin Cai; Diane Koontz; Carl R Fuhrman; Maria F Golzarri; Yushi Liu; Hiroto Hatabu; Mizuki Nishino; Tetsuro Araki; Paul F Dellaripa; Chester V Oddis; Ivan O Rosas; Dana P Ascherman
Journal:  Arthritis Rheumatol       Date:  2015-01       Impact factor: 10.995

10.  A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

Authors:  Talmadge E King; Williamson Z Bradford; Socorro Castro-Bernardini; Elizabeth A Fagan; Ian Glaspole; Marilyn K Glassberg; Eduard Gorina; Peter M Hopkins; David Kardatzke; Lisa Lancaster; David J Lederer; Steven D Nathan; Carlos A Pereira; Steven A Sahn; Robert Sussman; Jeffrey J Swigris; Paul W Noble
Journal:  N Engl J Med       Date:  2014-05-18       Impact factor: 91.245

View more
  16 in total

1.  Characteristics of rheumatoid arthritis patients undergoing reverse shoulder arthroplasty.

Authors:  Julio J Jauregui; J Paul Hovis; S Ashfaq Hasan
Journal:  Clin Rheumatol       Date:  2017-05-24       Impact factor: 2.980

Review 2.  Novel Biomarkers, Diagnostic and Therapeutic Approach in Rheumatoid Arthritis Interstitial Lung Disease-A Narrative Review.

Authors:  Alesandra Florescu; Florin Liviu Gherghina; Anca Emanuela Mușetescu; Vlad Pădureanu; Anca Roșu; Mirela Marinela Florescu; Cristina Criveanu; Lucian-Mihai Florescu; Anca Bobircă
Journal:  Biomedicines       Date:  2022-06-09

Review 3.  Rheumatoid Arthritis-Associated Interstitial Lung Disease: Current Concepts.

Authors:  Yoel Brito; Marilyn K Glassberg; Dana P Ascherman
Journal:  Curr Rheumatol Rep       Date:  2017-11-09       Impact factor: 4.592

4.  IgA Antibodies Directed Against Citrullinated Protein Antigens Are Elevated in Patients With Idiopathic Pulmonary Fibrosis.

Authors:  Joshua J Solomon; Scott Matson; Lindsay B Kelmenson; Jonathan H Chung; Stephen B Hobbs; Ivan O Rosas; Paul F Dellaripa; Tracy J Doyle; Sergio Poli; Anthony J Esposito; Ashley Visser; A Itzam Marin; Isabelle Amigues; Evans R Fernández Pérez; Kevin K Brown; Michael Mahler; David Heinz; Carlyne Cool; Kevin D Deane; Jeffrey J Swigris; M Kristen Demoruelle
Journal:  Chest       Date:  2019-12-23       Impact factor: 10.262

5.  Potential Metabolic Biomarkers to Identify Interstitial Lung Abnormalities.

Authors:  Yong Tan; Dongmei Jia; Zhang Lin; Baosheng Guo; Bing He; Cheng Lu; Cheng Xiao; Zhongdi Liu; Ning Zhao; Zhaoxiang Bian; Ge Zhang; Weidong Zhang; Xinru Liu; Aiping Lu
Journal:  Int J Mol Sci       Date:  2016-07-16       Impact factor: 5.923

Review 6.  Interstitial Lung Disease in Rheumatoid Arthritis Remains a Challenge for Clinicians.

Authors:  Elisabeth Bendstrup; Janne Møller; Sissel Kronborg-White; Thomas Skovhus Prior; Charlotte Hyldgaard
Journal:  J Clin Med       Date:  2019-11-21       Impact factor: 4.241

Review 7.  Efficacy and safety of mycophenolate mofetil in the treatment of rheumatic disease-related interstitial lung disease: a narrative review.

Authors:  Giulia Cassone; Marco Sebastiani; Caterina Vacchi; Gian Luca Erre; Carlo Salvarani; Andreina Manfredi
Journal:  Drugs Context       Date:  2021-01-15

Review 8.  Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows.

Authors:  Giulia Cassone; Andreina Manfredi; Caterina Vacchi; Fabrizio Luppi; Francesca Coppi; Carlo Salvarani; Marco Sebastiani
Journal:  J Clin Med       Date:  2020-04-10       Impact factor: 4.241

9.  Predicting outcomes in rheumatoid arthritis related interstitial lung disease.

Authors:  Joseph Jacob; Nikhil Hirani; Coline H M van Moorsel; Srinivasan Rajagopalan; John T Murchison; Hendrik W van Es; Brian J Bartholmai; Frouke T van Beek; Marjolijn H L Struik; Gareth A Stewart; Maria Kokosi; Ryoko Egashira; Anne Laure Brun; Gary Cross; Joseph Barnett; Anand Devaraj; George Margaritopoulos; Ronald Karwoski; Elisabetta Renzoni; Toby M Maher; Athol U Wells
Journal:  Eur Respir J       Date:  2019-01-03       Impact factor: 16.671

10.  Pirfenidone for the treatment of interstitial lung disease associated to rheumatoid arthritis: a new scenario is coming?

Authors:  Giulia Cassone; Marco Sebastiani; Caterina Vacchi; Stefania Cerri; Carlo Salvarani; Andreina Manfredi
Journal:  Respir Med Case Rep       Date:  2020-04-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.